Heather Huet is Head of Oncology Strategic Operations, OBU at Takeda. Dr. Huet also serves as Head, Portfolio & Strategy, OTAU at Takeda. She joined the company in June 2020 and is focused on strategizing the future of the pipeline, while also working with program teams on current prioritization activities.
Prior to joining Takeda, Dr. Huet was Head of Program Leadership and Portfolio Management at Unum Therapeutics, a biotechnology company focused on discovery and clinical development of next-generation engineered cell therapies, where she was responsible for the strategy and execution of clinical-stage-product candidates and managing strategic partnerships.
Before Unum Therapeutics, Dr. Huet spent 5 years at Novartis as a Senior Investigator and Lab Head, Oncology Biotherapeutics. There, she led multiple global, cross-functional project teams that progressed novel large-molecule therapeutics from target validation to clinical trials, including antibody drug conjugates (ADC), nanobodies, glyco-engineered ADCC-enhanced antibodies and CAR T cell therapy. Prior to Novartis, Dr. Huet spent 10 years at Biogen leading drug-discovery programs for oncology.
Dr. Huet received a BS with Honors from the University of Texas at Austin and a PhD in Virology from Harvard University.